Cigall Kadoch

Founder at Foghorn Therapeutics, Inc.

Cigall Kadoch

Cigall Kadoch

Founder at Foghorn Therapeutics, Inc.

Overview
Career Highlights

Foghorn Therapeutics, Inc.

RelSci Relationships

3114

Number of Boards

3

Birthday

1985

Age

36

Number of Awards

5

Relationships
RelSci Relationships are individuals Cigall Kadoch likely has professional access to. A relationship does not necessarily indicate a personal connection.

President & Chief Executive Officer at Foghorn Therapeutics, Inc.

Relationship likelihood: Strong

Advisor Partner at Flagship Pioneering

Relationship likelihood: Strong

Scientific Co-Founder at Inari Agriculture, Inc.

Relationship likelihood: Strong

Interim Executive Vice President & Chief Operating Officer & Chief Scientific Officer at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Managing Partner at Flagship Pioneering

Relationship likelihood: Strong

Owner at Foghorn Therapeutics, Inc.

Relationship likelihood: Strong

President Emeritus & Arthur Kingsley Porter University Professor at Harvard University

Relationship likelihood: Strong

Chief Financial Officer at Foghorn Therapeutics, Inc.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Evelo Biosciences, Inc.

Relationship likelihood: Strong

Co-Founder at Amplyx Pharmaceuticals, Inc.

Relationship likelihood: Strong

Paths to Cigall Kadoch
Potential Connections via
Relationship Science
You
Cigall Kadoch
Founder at Foghorn Therapeutics, Inc.
Education
PhD in Cancer Biology
Class of 2012

A leader in the Biomedical Revolution, Stanford Medicine has a long tradition of leadership in pioneering research, creative teaching protocols and effective clinical therapies. Our close proximity to the resources of the university—including the Schools of Business, Law, Humanities and Sciences and Engineering—our seamless relationship with our affiliated adult and children’s hospitals and our ongoing associations with the entrepreneurial endeavors of Silicon Valley make us uniquely positioned to accelerate the pace at which new knowledge is turned into tangible health benefits.

BA in Molecular & Cellular Biology
Class of 2007

University of California Berkeley National rankings: In a National Research Council analysis of 212 doctoral programs at American universities, 48 Berkeley programs place among the top 10 nationwide. Faculty awards and honors: There are 8 Nobel Laureates, 32 MacArthur Fellows, and 4 Pulitzer Prize winners among the current faculty. History of UC Berkeley: Historical highlights, arranged by topic, following the campus's development — from UC's founding in 1868 to a turn-of-the-century building boom, a research explosion in the 1930s, the Free Speech Movement of the '60s, and Berkeley's key role today in science and technology revolutions. Timeline of discoveries and contributions by UC Berkeley scholars. Traditions of Cal: Who was the Angel of Death? What's with the "Big C" up there in the hills — and why is it sometimes green? Who wears Oski's jolly bear head and size 54 yellow sweater? Tours and webcams: Check out what's happening on Sproul Plaza, the campus's true heart. See stunning live views of the Bay Area from the Lawrence Hall of Science's perch in the Berkeley hills. Chancellor and administration: Information on Chancellor Robert Birgeneau, Executive Vice Chancellor and Provost George W. Breslauer, and how the university is organized. Organizational charts are included. UC System overview and links: On the campuses, laboratories, and medical centers that comprise UC's public educational system, as well as UC's K-12 partnerships, economic impact, and agriculture and environmental resources.

Memberships
Institute Member
Current

The Broad Institute evolved from a decade of informal and successful research collaborations among scientists in the MIT and Harvard communities. In 1990, the Whitehead Institute/MIT Center for Genome Research (WICGR) was founded, and it soon became an international leader in the field of genomics and a flagship of the Human Genome Project. As early as 1995, WICGR scientists recognized the need to bring the power of genomics to the understanding of human disease. It launched pilot projects in genomic medicine, forming an unofficial collaborative network among scientists from across MIT and Harvard who pioneered new approaches to cancer and human genetics. In parallel, Harvard Medical School-based scientists established the Institute of Chemistry and Cell Biology (ICCB) in 1998, to facilitate the pursuit of chemical genetics as an academic discipline and a tool to further understand human biology and disease. In 2002, the ICCB was awarded an Initiative for Chemical Genetics (ICG) grant from the National Cancer Institute, and its successful Investigator-Initiated Screening Program facilitated small molecule screening projects for more than 80 research groups worldwide. These projects demonstrated the power of enabling scientists to collaborate to tackle the major challenges in molecular medicine. It was clear that a new type of formal organization was required — open, collaborative, interdisciplinary, and able to organize projects at any scale. In addition, it was important that the complementary expertise of the genomic scientists and the chemical biologists across MIT and Harvard be brought together in one place to drive the transformation of medicine with molecular knowledge. Discussions in 2002-2003 among Eli and Edythe Broad, MIT, Harvard and its affiliated hospitals, and the Whitehead Institute shaped the vision for this new institute. The extraordinary generosity of Eli and Edythe Broad, through their founding gift of $100 million (later doubled to $200 million) made it possible to formally announce the new institute in June 2003 and to launch it in May 2004. Less than four years after its launch, the Broads gave an unprecedented gift of $400 million in September 2008 to permanently endow the institute, providing long-term sustainability for its unique model of collaborative, inter-institutional research.

Career History
Founder
2015 - Current

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

Principal Investigator, Pediatric Oncology
Current

Since its founding in 1947, Dana-Farber has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. Read about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities.

Assistant Professor of Pediatrics
Current

Harvard Medical School (HMS) is the graduate medical school of Harvard University. It is located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts.The school was founded by John Warren on September 19, 1782, with Benjamin Waterhouse, and Aaron Dexter.

Investments
Details Hidden

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

Public Holdings
Restricted data only for RelSci Professional users.
Awards & Honors
2016
PopSci's Brilliant 10
2014
Forbes - 30 under 30, Science & Health
2013
Forbes - 30 under 30, Science & Health
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Cigall Kadoch. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Cigall Kadoch's profile does not indicate a business or promotional relationship of any kind between RelSci and Cigall Kadoch.